TOKYO & BLOOMINGTON, Minn.--(BUSINESS WIRE)--Eisai Co., Ltd. (Tokyo, TSE: 4523) (“Eisai”) and MGI PHARMA, INC. (NASDAQ: MOGN) (“MGI PHARMA”) announced today that the Federal Trade Commission has granted early termination of the statutory waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), applicable to the acquisition of MGI PHARMA by Eisai.
